Lindane

Hypersensitivity. Uncontrolled seizure disorders, conditions which may increase systemic absorption (e.g. crusted scabies, atopic dermatitis, psoriasis). Premature infants. Lactation.

Patient with history of seizures, previous head trauma, CNS tumour, HIV infection, or other conditions which may increase risk of seizures (e.g. excessive alcohol consumption); other certain skin conditions. Patient weighing <50kg. Hepatic impairment. Infants, children, and elderly. Pregnancy. Not indicated as 1st-line treatment. Avoid using oil treatments, or oil-based hair dressings or conditioners prior to and after application on the affected area. Patient counselling Itching may persist even after successful treatment and not necessarily an indication for further treatment. Monitoring Parameters Monitor for signs and symptoms of neurologic toxicity.

General disorders and administration site conditions: Pain. Nervous system disorders: Headache, paraesthesia, dizziness. Skin and subcutaneous tissue disorders: Contact dermatitis, rash, alopecia, pruritus, urticaria.
Potentially Fatal: Neurotoxicity (e.g. seizures).

May increase risk of seizures with drugs that may lower the seizure threshold (e.g. antipsychotics, antidepressants, centrally active anticholinesterases, theophylline, isoniazid, meperidine, ciclosporin, mycophenolate mofetil, tacrolimus, penicillins, imipenem, quinolones, chloroquine, pyrimethamine, radiographic contrast agents, methocarbamol).

Topical Antifungals & Antiparasites

P03AB02 - lindane ; Belongs to the class of chlorine-containing agents used as ectoparasiticides.